| Sep 10 |
Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
|
| Sep 10 |
Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting
|
| Sep 6 |
Verastem's Path To FDA Approval: High-Risk, High-Reward Oncology Opportunity
|
| Sep 3 |
Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024
|
| Aug 8 |
Verastem: Q2 Earnings Snapshot
|
| Aug 8 |
Verastem Non-GAAP EPS of -$0.61 beats by $0.45
|
| Aug 8 |
Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates
|
| Jul 29 |
Verastem gets FDA orphan drug status for pancreatic cancer therapy
|
| Jul 29 |
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer
|
| Jul 24 |
Why Enphase Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
